Analytical Data
-
基因名
FMO2
- Application
-
别名
FMO2;Flavin-containing monooxygenase 2
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P31512
-
表达区间
1-558aa
-
氨基酸序列
MAKKVAVIGAGVSGLSSIKCCVDEDLEPTCFERSDDIGGLWKFTESSKDGMTRVYKSLVTNVCKEMSCYSDFPFHEDYPNFMNHEKFWDYLQEFAEHFDLLKYIQFKTTVCSITKRPDFSETGQWDVVTETEGKQNRAVFDAVMVCTGHFLNPHLPLEAFPGIHKFKGQILHSQEYKIPEGFQGKRVLVIGLGNTGGDIAVELSRTAAQVLLSTRTGTWVLGRSSDWGYPYNMMVTRRCCSFIAQVLPSRFLNWIQERKLNKRFNHEDYGLSITKGKKAKFIVNDELPNCILCGAITMKTSVIEFTETSAVFEDGTVEENIDVVIFTTGYTFSFPFFEEPLKSLCTKKIFLYKQVFPLNLERATLAIIGLIGLKGSILSGTELQARWVTRVFKGLCKIPPSQKLMMEATEKEQLIKRGVFKDTSKDKFDYIAYMDDIAACIGTKPSIPLLFLKDPRLAWEVFFGPCTPYQYRLMGPGKWDGARNAILTQWDRTLKPLKTRIVPDSSKPASMSHYLKAWGAPVLLASLLLICKSSLFLKLVRDKLQDRMSPYLVSLWRG
-
分子量
63.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FMO2 (flavin-containing monooxygenase 2) is an important enzyme involved in the metabolism of various xenobiotics and endogenous compounds, playing a key role in drug metabolism and detoxification processes. Research on FMO2 has gained significant attention due to its potential implications in pharmacogenomics, as genetic variations in the FMO2 gene can influence enzyme activity and, consequently, individual responses to medications. Understanding the structure and function of FMO2 through the study of its recombinant protein is essential for elucidating its catalytic mechanisms and substrate specificity. Furthermore, FMO2 exhibits tissue-specific expression, predominantly in the liver and lungs, which adds complexity to its role in different physiological contexts. Advances in recombinant protein technology have allowed for the production of functional FMO2 protein, facilitating detailed investigations into its enzymatic properties and interactions with various substrates. This research is critical not only for the development of personalized medicine approaches but also for providing insights into the metabolic pathways that govern drug efficacy and toxicity. By employing techniques such as X-ray crystallography and mass spectrometry, scientists aim to obtain a comprehensive understanding of FMO2, paving the way for novel therapeutic strategies and improved drug design.












